Business Context and Reporting Period
Company: Sheffield Pharmaceuticals, Inc. (formerly Sheffield Medical Technologies, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1997
Business Stage: Development stage enterprise with no commercial product sales to date.
Core Focus: Development and commercialization of the Premaire(TM) Metered Solution Inhaler (MSI System) for respiratory diseases (asthma, COPD) and out-licensing early-stage biomedical technologies (cancer, HIV/AIDS).
Key Financial Metrics
| Metric | 1997 | 1996 |
|---|---|---|
| Total Revenue | $556,914 | $673,664 |
| Net Loss | $(9,489,138) | $(7,008,889) |
| Loss Per Share (Basic) | $(0.80) | $(0.65) |
| Accumulated Deficit | $(36,157,290) | $(26,588,652) |
| Cash and Cash Equivalents | $393,608 | $1,979,871 |
| Working Capital (Net) | $(837,564) | $1,433,773 |
| Long-term Debt & Redeemable Preferred | $4,019,263 | $27,206 |
Note: Revenue consists primarily of sublicense fees and interest income. The company has no operating revenue from product sales.
Material Changes vs. Prior Period
- Increased Losses: Net loss increased by approximately $2.48 million (35%) compared to 1996, driven by a one-time $1.65 million charge for the acquisition of in-process technology (Camelot Pharmacal) and increased general and administrative expenses.
- Liquidity Deterioration: Working capital shifted from a positive $1.43 million in 1996 to a negative $837,564 in 1997. Cash on hand dropped by over $1.5 million due to heavy R&D expenditures and the acquisition of the Premaire(TM) MSI System technology.
- Debt Structure: The company issued $1.75 million in 6% Convertible Subordinated Debentures in late 1997, significantly increasing long-term obligations compared to the prior year.
- Revenue Decline: Total revenue decreased by $116,750, primarily due to lower interest income resulting from the deployment of cash reserves into the MSI System acquisition.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Independent auditors have issued a report stating that the company's recurring losses and net deficit raise substantial doubt about its ability to continue as a going concern. Management states survival through 1998 is dependent on obtaining additional financing.
- Capital Needs: The company estimates it requires approximately $17.5 million in committed and anticipated funding for R&D after December 31, 1997. Current cash ($393,608) is insufficient to meet trade payables ($887,782) and research obligations ($470,768).
- Recent Financing (Post-Period): In April 1998, the company secured $650,000 via an equity investment from Zambon Group SpA and $1.25 million via a Series B Convertible Preferred Stock offering. These funds were used to pay a delayed DM 2.0 million license fee to Siemens AG.
- Strategic Partnerships: The company is actively seeking partners for foreign marketing of respiratory drugs and out-licensing early-stage technologies (e.g., HIV/AIDS, cancer) to reduce development costs.
- Regulatory Risks: No products have received FDA approval. Commercialization is contingent on successful clinical trials and regulatory approvals, which are costly and time-consuming.
- Legal Contingency: The company is a defendant in a lawsuit (Dr. Bonnie S. Dunbar v. Sheffield) alleging breach of contract and fraud regarding stock options. An unfavorable outcome could have a material adverse effect.
Investor Verification Checklist
- Financing Status: Verify the status of the definitive agreement with Zambon Group SpA and the sufficiency of the $1.9 million raised in April 1998 to cover the estimated $17.5 million R&D gap.
- Siemens Payment: Confirm that the DM 2.0 million payment to Siemens AG (due Jan 1998, paid April 1998) has been settled to avoid forfeiture of the Premaire(TM) MSI System rights.
- Stock Dilution: Assess the dilutive impact of outstanding options (approx. 4.78 million shares), warrants, and convertible debentures ($1.55 million principal) relative to the 12.65 million common shares outstanding.
- Legal Exposure: Monitor the progress of the Dunbar litigation and potential settlement costs.
- Listing Status: Verify if the company meets AMEX listing criteria, as it currently has a stockholders' deficit and sustained losses, risking delisting to the over-the-counter market.